JP Patent

JP2023553532A — 癌の処置のための併用療法

Assigned to エラスカ，インク． · Expires 2023-12-21 · 2y expired

What this patent protects

【解決手段】本開示は、ＳＨＰ２阻害剤およびＥＧＦＲ阻害剤の併用療法を用いて癌を処置する方法を提供する。【選択図】図１Ａ

USPTO Abstract

【解決手段】本開示は、ＳＨＰ２阻害剤およびＥＧＦＲ阻害剤の併用療法を用いて癌を処置する方法を提供する。【選択図】図１Ａ

Drugs covered by this patent

osimertinib-mesylate (OSIMERTINIB MESYLATE)

Patent Metadata

Patent number: JP2023553532A
Jurisdiction: JP
Classification: —
Expires: 2023-12-21
Drug substance claim: No
Drug product claim: No
Assignee: エラスカ，インク．
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.